miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1
Carcinogenesis · 2024
DOI: 10.1093/carcin/bgac093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carcinogenesis, 2024. Verfasst von Daji Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Xinmin Street, Changchun 130021, China. Hauptthemen laut MEDLINE: MicroRNAs, Liver Neoplasms, Neoplastic Stem Cells, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
MicroRNAs (miRNAs) were involved in tumorigenesis, progression, recurrence and drug resistance of hepatocellular carcinoma (HCC). However, few miRNAs have been identified and entered clinical practice. We show here that miR-4461 expression is reduced in liver cancer stem cells (CSCs) and predicts the poor prognosis of HCC patients. Knockdown of miR-4461 enhances the self-renewal and tumorigenicity of liver CSCs. Conversely, forced miR-4461 expression inhibits liver CSCs self-renewal and tumorigenesis. Mechanically, miR-4461 directly targets sirtuin 1 (SIRT1) via binding to its 3ʹ untranslated region in liver CSCs. The correlation of miR-4461 and SIRT1 was confirmed in human HCC patients’ tissues. Additionally, we found that miR-4461 overexpression hepatoma cells are more sensitive to cisplatin treatment. Patient-derived xenografts also showed that miR-4461 high HCC xenografts are sensitive to cisplatin treatment. Clinical cohort analysis further confirmed that HCC patients with high miR-4461 benefited more from transcatheter arterial chemoembolization treatment. In conclusion, our findings revealed the crucial role of miR-4461 in liver CSCs expansion and cisplatin response, rendering miR-4461 as an optimal target for the prevention and intervention of HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Xinmin Street, Changchun 130021, China.
- Department of Emergency, The 964th Hospital of the Chinese People's Liberation Army, Changchun, China.
- Department of Hepatic Surgery, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China.
- Department of Integrative Medicine, Third Affiliated Hospital of Second Military Medical University, Shanghai 200438, China.
ORCID-Profile: Ziyu Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, D., Zhang, P., Yang, Z., Hou, G., & Yang, Z. (2024). miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1. Carcinogenesis. https://doi.org/10.1093/carcin/bgac093
Vancouver
Yang D, Zhang P, Yang Z, Hou G, Yang Z. miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1. Carcinogenesis. 2024. doi:10.1093/carcin/bgac093
BibTeX
@article{Yang2024,
author = {Yang, Daji and Zhang, Ping and Yang, Ziting and Hou, Guojun and Yang, Ziyu},
title = {miR-4461 inhibits liver cancer stem cells expansion and chemoresistance via regulating SIRT1},
journal = {Carcinogenesis},
year = {2024},
doi = {10.1093/carcin/bgac093}
}
EUVIMED